Illustration: Sarah Grillo/Axios

Amgen and Novartis jointly developed and sold the first FDA-approved drug to prevent migraines, which hit the market last year. But now their alliance is crumbling and they're suing each other.

The big picture: Everyone is so mad. These pharma giants are throwing every legal punch possible because there is so much money at stake.

  • Because Aimovig was the first in this class of migraine drugs to get FDA approval, it got the upper hand and controls 53% of the market.
  • U.S. sales of Aimovig were $119 million in 2018, but Wall Street analysts think sales could hit almost $2 billion by 2025.

The intrigue: Everything revolves around the contracts that Amgen and Novartis signed, which outlined how they would collaborate on research and marketing for Aimovig.

  • Amgen terminated the contracts on April 2, alleging a subsidiary of Novartis violated the terms by helping another company, Alder BioPharmaceuticals, make a competing migraine drug. Novartis admitted this after the fact, yet said it would still help Alder for another 5 years, according to Amgen's lawsuit.
  • Novartis denies the claims, arguing it didn't significantly breach their agreements because Alder's pending product isn't a true competitor. Instead, Novartis asserted Amgen is inappropriately ending the partnership "to keep the Aimovig profits for itself" and before Novartis "has come close to earning a return on its investment."

Go deeper:

Go deeper

Updated 1 hour ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Global: Total confirmed cases as of 9:30 p.m. ET: 19,499,341 — Total deaths: 723,881 — Total recoveries — 11,864,471Map.
  2. U.S.: Total confirmed cases as of 9:30p.m. ET: 4,999,836 — Total deaths: 162,382 — Total recoveries: 1,643,118 — Total tests: 61,080,587Map.
  3. Politics: Trump signs 4 executive actions on coronavirus aid — Democrats slam Trump, urge GOP to return to negotiations
  4. Public health: Fauci says chances are "not great" that COVID-19 vaccine will be 98% effective — 1 in 3 Americans would decline COVID-19 vaccine.
  5. Science: Indoor air is the next coronavirus frontline.
  6. Schools: How back-to-school is playing out in the South as coronavirus rages on — Princeton, Johns Hopkins, Howard to hold fall classes online.

Trump signs 4 executive actions on coronavirus aid

President Trump speaking during a press conference on Aug. 8. Photo: Jim Watson/AFP via Getty Images

President Trump on Saturday signed four executive actions to provide relief from economic damage sustained during the coronavirus pandemic after talks between the White House and Democratic leadership collapsed Friday afternoon.

Why it matters: Because the Constitution gives Congress the power to appropriate federal spending, Trump has limited authority to act unilaterally — and risks a legal challenge if congressional Democrats believe he has overstepped.

9 hours ago - World

What's next for Lebanon after the Beirut explosion

Photo: Houssam Shbaro/Anadolu Agency via Getty Images

Beirut residents are still clearing rubble from streets that appear war-torn, days after a blast that shocked the country and horrified the world.

Why it matters: The explosion is likely to accelerate a painful cycle Lebanon was already living through — discontent, economic distress, and emigration.